PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 19843060-5 2009 RESULTS: (i) The CYP3A4 and CYP1A2 inhibitors ketoconazole and fluvoxamine inhibited CLZ oxidation to varying extents in individual microsomal fractions. Fluvoxamine 63-74 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 28-34 20435083-3 2010 All three activities were substantially inhibited (>or=75%) by the CYP1 inhibitor alpha-naphthoflavone, whereas only MROD and CECOD were substantially inhibited by the CYP1A2-preferential inhibitor fluvoxamine. Fluvoxamine 201-212 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 171-177 21277363-4 2011 Fluvoxamine maleate, gemfibrozil, amiodarone hydrochloride, omeprazole, quinidine, diethyldithiocarbamic acid and ketoconazole were successfully applied as test inhibitors for CYP1A2, CYP2C8, CYP2C9, CYP2C19*1, CYP2D6*1, CYP2E1 and CYP3A4/5 in HLMs, respectively. Fluvoxamine 0-19 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 176-182 19593168-4 2009 In patients comedicated with fluvoxamine, a strong CYP1A2 inhibitor, clozapine and norclozapine concentrations correlate with CYP3A activity (r = 0.44, P = 0.075; r = 0.63, P = 0.007, respectively). Fluvoxamine 29-40 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 51-57 19225771-1 2009 PURPOSE: Fluvoxamine (FVX) is metabolized by cytochrome P450 (CYP) 2D6 and CYP1A2 and inhibits CYP3A4. Fluvoxamine 9-20 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 75-81 19225771-1 2009 PURPOSE: Fluvoxamine (FVX) is metabolized by cytochrome P450 (CYP) 2D6 and CYP1A2 and inhibits CYP3A4. Fluvoxamine 22-25 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 75-81 18691982-11 2008 Fluoxetine and paroxetine are potent inhibitors of CYP2D6, fluvoxamine markedly inhibits CYP1A2 and CYP2C19, and nefazodone is a substantial inhibitor of CYP3A4. Fluvoxamine 59-70 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 89-95 18816299-3 2008 In vitro, fluvoxamine, tolfenamic acid, mefenamic acid and rofecoxib potently inhibited CYP1A2 [the 50% inhibitory concentration (IC(50)) < 10 microM]. Fluvoxamine 10-21 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 88-94 18438654-7 2008 CONCLUSION: Co-administration of the CYP1A2 inhibitor fluvoxamine with ramosetron resulted in an interaction. Fluvoxamine 54-65 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 37-43 17823102-5 2007 The primary pharmacokinetic interactions with smoking occur with drugs that are CYP1A2 substrates, such as caffeine, clozapine, fluvoxamine, olanzapine, tacrine, and theophylline. Fluvoxamine 128-139 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 80-86 18690879-2 2008 Recent human studies have shown that the magnitude of inhibitory interactions caused by the reversible CYP1A2 inhibitor fluvoxamine decreases as liver function worsens, and virtually vanishes in patients with more advanced hepatocellular insufficiency. Fluvoxamine 120-131 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 103-109 17504220-6 2007 Interactions mediated by potent CYP1A2 inhibitors (such as fluvoxamine) or inducers (like cigarette smoke) appear to be consistent, predictable and usually clinically significant. Fluvoxamine 59-70 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 32-38 17214606-12 2007 Of a particular clinical significance is the interaction between fluvoxamine, a potent CYP1A2 inhibitor, and clozapine. Fluvoxamine 65-76 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 87-93 17596106-1 2007 OBJECTIVE: To investigate the effects of steady-state dosing of fluvoxamine, an inhibitor of cytochrome P450 (CYP) 1A2 and CYP2C19, on the pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 (PDE4) inhibitor and its pharmacodynamically active metabolite roflumilast N-oxide. Fluvoxamine 64-75 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 93-118 17596106-9 2007 CONCLUSION: Co-administration of roflumilast and fluvoxamine affects the disposition of roflumilast and its active metabolite roflumilast N-oxide most likely via a potent dual pathway inhibition of CYP1A2 and CYP2C19 by fluvoxamine. Fluvoxamine 49-60 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 198-204 17166674-6 2007 The fact that fluvoxamine, a potent cytochrome P450 (CYP) 1A2 inhibitor, reduced tacrine toxicity and the expression of the CYP 1A2 gene was maintained in gel entrapped hepatocytes, but not in hepatocyte monolayers, could illustrate a close association between CYP 1A2 expression levels and tacrine toxicity. Fluvoxamine 14-25 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 36-61 17166674-6 2007 The fact that fluvoxamine, a potent cytochrome P450 (CYP) 1A2 inhibitor, reduced tacrine toxicity and the expression of the CYP 1A2 gene was maintained in gel entrapped hepatocytes, but not in hepatocyte monolayers, could illustrate a close association between CYP 1A2 expression levels and tacrine toxicity. Fluvoxamine 14-25 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 124-131 17166674-6 2007 The fact that fluvoxamine, a potent cytochrome P450 (CYP) 1A2 inhibitor, reduced tacrine toxicity and the expression of the CYP 1A2 gene was maintained in gel entrapped hepatocytes, but not in hepatocyte monolayers, could illustrate a close association between CYP 1A2 expression levels and tacrine toxicity. Fluvoxamine 14-25 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 261-268 17596106-9 2007 CONCLUSION: Co-administration of roflumilast and fluvoxamine affects the disposition of roflumilast and its active metabolite roflumilast N-oxide most likely via a potent dual pathway inhibition of CYP1A2 and CYP2C19 by fluvoxamine. Fluvoxamine 220-231 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 198-204 14749694-10 2004 The extent of fluvoxamine-lidocaine interaction decreases as liver function worsens, most likely because of the concomitant decrease in the hepatic level of CYP1A2. Fluvoxamine 14-25 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 157-163 16985100-8 2006 Fluvoxamine decreased the rofecoxib-caused inactivation of CYP1A2 in a concentration-dependent manner. Fluvoxamine 0-11 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 59-65 17045169-5 2006 Dynamic PET studies using were performed on three controls and two patients, one treated with the antidepressant and inhibitor of cytochrome CYP1A2 fluvoxamine, the other suffering from liver cirrhosis. Fluvoxamine 148-159 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 141-147 16893613-5 2006 It turns out that the medication fluvoxamine approved by the FDA for the treatment of obsessive compulsive disorder is a potent inhibitor of the CYP1A2 enzyme, with the effect that co-administration of ramelton and fluvoxamine increases blood levels of ramelton by 100-200 fold. Fluvoxamine 33-44 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 145-151 16893613-5 2006 It turns out that the medication fluvoxamine approved by the FDA for the treatment of obsessive compulsive disorder is a potent inhibitor of the CYP1A2 enzyme, with the effect that co-administration of ramelton and fluvoxamine increases blood levels of ramelton by 100-200 fold. Fluvoxamine 215-226 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 145-151 16236038-1 2005 BACKGROUND: Coadministration of fluvoxamine impairs the clearance of caffeine and prolongs its elimination half-life, which is attributable to inhibition of CYP1A2 by fluvoxamine. Fluvoxamine 32-43 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 157-163 16236038-1 2005 BACKGROUND: Coadministration of fluvoxamine impairs the clearance of caffeine and prolongs its elimination half-life, which is attributable to inhibition of CYP1A2 by fluvoxamine. Fluvoxamine 167-178 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 157-163 15738749-5 2005 The present prospective study tested the hypothesis that olanzapine steady-state doses can be significantly decreased by coadministration of a low subclinical dose of fluvoxamine, a potent inhibitor of cytochrome P450 1A2. Fluvoxamine 167-178 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 202-221 15738749-11 2005 4"-N-desmethylolanzapine/olanzapine metabolic ratio decreased from 0.45 +/- 0.20 at baseline to 0.25 +/- 0.11 at week 6, suggesting inhibition of the cytochrome P450 1A2-mediated olanzapine 4"-N-demethylation by fluvoxamine (P < 0.05). Fluvoxamine 212-223 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 150-169 15060511-12 2004 Inhibition of tizanidine-metabolizing enzyme(s), mainly CYP1A2, by fluvoxamine seems to explain the observed interaction. Fluvoxamine 67-78 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 56-62 16918719-2 2006 We studied the effect of co-administration of fluvoxamine (CYP1A2 inhibitor) and erythromycin (CYP3A4 inhibitor) on the pharmacokinetics of lidocaine in a double-blind, randomized, three-way cross-over study. Fluvoxamine 46-57 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 59-65 16918719-10 2006 We conclude that inhibition of CYP1A2 by fluvoxamine considerably reduces the presystemic metabolism of oral lidocaine and may increase the risk of lidocaine toxicity if lidocaine is ingested. Fluvoxamine 41-52 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 31-37 16678550-0 2006 Liver dysfunction markedly decreases the inhibition of cytochrome P450 1A2-mediated theophylline metabolism by fluvoxamine. Fluvoxamine 111-122 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 55-74 16678550-1 2006 BACKGROUND AND OBJECTIVES: In vivo inhibition of cytochrome P450 (CYP) 1A2 by fluvoxamine causes a reduction in the clearance of the high-extraction drug lidocaine, which decreases in proportion to the degree of liver dysfunction. Fluvoxamine 78-89 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 49-74 16678550-12 2006 Two mechanisms, as follows in order of importance, are responsible for the effect of liver dysfunction: (1) decreased sensitivity to fluvoxamine of CYP1A2-mediated biotransformations in the cirrhotic liver, probably resulting from reduced uptake of the inhibitory drug, and (2) reduced hepatic expression of CYP1A2, which makes its contribution to overall drug elimination less important. Fluvoxamine 133-144 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 148-154 16678550-12 2006 Two mechanisms, as follows in order of importance, are responsible for the effect of liver dysfunction: (1) decreased sensitivity to fluvoxamine of CYP1A2-mediated biotransformations in the cirrhotic liver, probably resulting from reduced uptake of the inhibitory drug, and (2) reduced hepatic expression of CYP1A2, which makes its contribution to overall drug elimination less important. Fluvoxamine 133-144 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 308-314 15845683-2 2005 We studied the effect of coadministration of the antidepressant fluvoxamine (CYP1A2 inhibitor) and antimicrobial drug erythromycin (CYP3A4 inhibitor) on lidocaine pharmacokinetics in a double-blind, randomized, three-way crossover study. Fluvoxamine 64-75 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 77-83 15845683-8 2005 We conclude that inhibition of CYP1A2 by fluvoxamine considerably reduces elimination of lidocaine and may increase the risk of lidocaine toxicity. Fluvoxamine 41-52 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 31-37 15545309-2 2004 Administration of a potent CYP1A2 inhibitor (eg, fluvoxamine) may alter the pharmacokinetics of olanzapine. Fluvoxamine 49-60 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 27-33 15199661-5 2004 Fluvoxamine is a potent inhibitor of CYP1A2 and CYP2C19 and a moderate inhibitor of CYP2C9. Fluvoxamine 0-11 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 37-43 14703714-4 2003 Fluoxetine and paroxetine are potent inhibitors of CYP2D6, fluvoxamine markedly inhibits CYP1A2 and CYP2C19, while nefazodone is a potent inhibitor of CYP3A4. Fluvoxamine 59-70 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 89-95 12695344-1 2003 A previous study suggested that fluvoxamine inhibition potency toward CYP1A2 is 10 times greater in vivo than in vitro. Fluvoxamine 32-43 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 70-76 12828569-10 2003 Inclusion of the CYP1A2 inhibitor fluvoxamine in the incubation mixture with human liver microsomes resulted in potent inhibition of tangeretin and genistein metabolism. Fluvoxamine 34-45 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 17-23 11955666-3 2002 Microsomal flavonoid metabolism was potently inhibited by the CYP1A2 inhibitors, fluvoxamine and -naphthoflavone. Fluvoxamine 81-92 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 62-68 12452751-8 2002 Fluvoxamine has the potential to inhibit CYP1A2, CYP2C9, CYP2C19, and CYP3A4 to a significant degree. Fluvoxamine 0-11 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 41-47 12352274-2 2002 In this study, pharmacokinetic interactions and clinical effects of adding the CYP1A2 inhibitor fluvoxamine to steady-state olanzapine was examined in patients suffering from schizophrenia. Fluvoxamine 96-107 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 79-85 12523495-8 2002 The obtained results suggest a strong inhibitory effect of perazine on human CYP1A2 activity with predicted Ki value similar to those of the known for CYP1A2 inhibitors, such as furafylline and fluvoxamine. Fluvoxamine 194-205 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 77-83 12523495-8 2002 The obtained results suggest a strong inhibitory effect of perazine on human CYP1A2 activity with predicted Ki value similar to those of the known for CYP1A2 inhibitors, such as furafylline and fluvoxamine. Fluvoxamine 194-205 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 151-157 11803239-6 2002 These findings are compatible with those in earlier reports that cytochrome P450 1A2 plays a major role in fluvoxamine metabolism. Fluvoxamine 107-118 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 65-84 11907488-0 2002 Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19). Fluvoxamine 35-46 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 88-106 11907488-1 2002 OBJECTIVES: Fluvoxamine is metabolized by the polymorphic cytochrome P450 (CYP) 2D6 and the smoking-inducible CYP1A2. Fluvoxamine 12-23 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 110-116 11907488-2 2002 Therapeutic doses of fluvoxamine inhibit both CYP1A2 and CYP2C19. Fluvoxamine 21-32 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 46-52 11907488-11 2002 At steady state, the 25 mg x 1 or x 2 fluvoxamine dose caused a pronounced inhibition of about 75% to 80% for both CYP1A2 and CYP2C19, whereas the inhibition after the lower 10 mg x 1 or x 2 dose was about 40% to 50%. Fluvoxamine 38-49 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 115-121 11907488-18 2002 A nontherapeutic oral daily dose of fluvoxamine is sufficient to provide a marked inhibition of both caffeine (CYP1A2) and omeprazole (CYP2C19) metabolism. Fluvoxamine 36-47 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 111-117 11876575-6 2002 Fluvoxamine is a potent CYP1A2 and CYP2C19 inhibitor, and a moderate CYP2C9, CYP2D6, and CYP3A4 inhibitor. Fluvoxamine 0-11 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 24-30 12038880-11 2002 Within the group of SSRIs, fluoxetine and paroxetine are potent inhibitors of CYP2D6, while fluvoxamine predominantly affects CYP1A2 and CYP2C19 activity. Fluvoxamine 92-103 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 126-132 11519155-5 2001 Fluvoxamine, an SSRI, is a potent inhibitors for CYP1A2 and CYP2C19, moderate for CYP3A4 and weak for CYP 2D6. Fluvoxamine 0-11 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 49-55 11719727-1 2001 OBJECTIVE: Several reports indicate that fluvoxamine decreases the clearance of cytochrome P4501A2 (CYP1A2) substrates. Fluvoxamine 41-52 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 80-98 11719727-1 2001 OBJECTIVE: Several reports indicate that fluvoxamine decreases the clearance of cytochrome P4501A2 (CYP1A2) substrates. Fluvoxamine 41-52 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 100-106 11719727-2 2001 This study compared in vitro and in vivo inhibition potencies of fluvoxamine toward CYP1A2 with an approach based on inhibition constants (K(i)) determined in vitro and in vivo. Fluvoxamine 65-76 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 84-90 11719727-4 2001 Fluvoxamine in vivo inhibition constants (K(i)iv) for CYP1A2 were obtained from an investigation of single-dose theophylline (250 mg) disposition in 9 healthy volunteers receiving steady-state (9 days) fluvoxamine at 3 doses (0, 25, or 75 mg/d) in a randomized crossover design. Fluvoxamine 0-11 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 54-60 11791895-1 2001 OBJECTIVE: Previous studies have shown that fluvoxamine is metabolized by CYP1A2 and CYP2D6, but there is no information on the impact the various CYP enzymes have on the different metabolic pathways of fluvoxamine biotransformation. Fluvoxamine 44-55 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 74-80 11791895-12 2001 CONCLUSION: These results indicate that CYP2D6 catalyzes the major metabolic pathway of fluvoxamine, whereas CYP1A2 seems to catalyze other less important pathways. Fluvoxamine 88-99 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 109-115 11791895-13 2001 Both the CYP2D6 and the CYP1A2 pathways seem to be saturated in parallel with increasing fluvoxamine dosage. Fluvoxamine 89-100 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 24-30 11704898-7 2001 Inhibition of CYP1A2 by fluvoxamine yields increased concentrations; however, clinically relevant CYP2D6 inhibition was observed only in combination with additional disposition factors, such as female gender or old age. Fluvoxamine 24-35 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 14-20 11599655-2 2001 METHODS: Quantitative CYP1A1- and CYP1A2-mediated EROD activities were determined in 42 human livers using differential inhibition of EROD by fluvoxamine. Fluvoxamine 142-153 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 34-40 11477325-5 2001 This indicated that fluvoxamine inhibits the metabolism of olanzapine, probably because of inhibition of cytochrome P450 (CYP) 1A2, whereas sertraline is unlikely to interfere with the metabolism of olanzapine. Fluvoxamine 20-31 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 105-130 11249525-5 2000 Differences in the metabolic balance between hepatic P450 (especially CYP 1A2) and MAO-A inactivation lead to potential drug interactions for all TELs with the oral contraceptive pill (OCP), fluvoxamine and the quinilone antibiotics (with increased triptan levels). Fluvoxamine 191-202 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 70-77 11240973-1 2001 BACKGROUND AND OBJECTIVES: Fluvoxamine, a selective serotonin reuptake inhibitor, is known to inhibit several hepatic cytochrome P450 (CYP) isozymes, in particular CYP1A2. Fluvoxamine 27-38 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 164-170 11317475-7 2001 CONCLUSIONS: Our results strongly suggest that 6-hydroxylation, the main metabolic pathway of melatonin, is mediated mainly, but not exclusively, by CYP1A2, the high-affinity enzyme involved in melatonin metabolism, confirming the observation that a single oral dose of fluvoxamine increases nocturnal serum melatonin levels in healthy subjects. Fluvoxamine 270-281 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 149-155 11791889-12 2001 These results indicate that CYP 3A4 inhibition may not be clinically significant compared to CYP 1A2, as previous studies show a dramatic increase in CLZ plasma concentrations with fluvoxamine (CYP 1A2 inhibitor). Fluvoxamine 181-192 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 194-201 24921690-9 2001 Potent inhibitors of CYP 1A2 such as fluvoxamine can precipitate caffeine toxicity. Fluvoxamine 37-48 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 21-28 10982203-2 2000 Previous reports have shown that fluvoxamine can increase plasma clozapine concentrations by inhibition of cytochrome P450 (CYP) 1A2. Fluvoxamine 33-44 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 107-132 10774624-6 2000 Fluvoxamine is metabolized to inactive metabolites by CYP1A2 and CYP2D6. Fluvoxamine 0-11 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 54-60 11085201-3 2000 Relative to other SSRIs, fluvoxamine is a weak inhibitor of cytochrome P450 (CYP) 2D6, a moderate inhibitor of CYP2C19 and CYP3A4 and a potent inhibitor of CYP1A2. Fluvoxamine 25-36 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 156-162 10877005-0 2000 Fluvoxamine but not citalopram increases serum melatonin in healthy subjects-- an indication that cytochrome P450 CYP1A2 and CYP2C19 hydroxylate melatonin. Fluvoxamine 0-11 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 114-120 10877005-6 2000 FLU inhibits CYP1A2 potently, and to some extent also CYP2C19, whereas CIT is without such an effect. Fluvoxamine 0-3 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 13-19 10653206-6 2000 Fluvoxamine inhibited CYP1A2 and 2C19 with the highest affinities (Ki values of 0.041 and 0.087 microM, respectively). Fluvoxamine 0-11 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 22-28 10456487-3 1999 The aim of this study was to establish whether the potent CYP1A2 inhibitor fluvoxamine in clinically relevant doses could inhibit tacrine metabolism. Fluvoxamine 75-86 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 58-64 10674711-9 2000 Paroxetine and, to a lesser degree, fluoxetine and norfluoxetine are potent inhibitors of CYP2D6 and fluvoxamine of CYP1A2 and CYP2C19. Fluvoxamine 101-112 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 116-122 10587283-6 1999 In conclusion, fluvoxamine markedly interferes with the metabolism of THD, probably at the CYP2C19 and/or CYP1A2 enzyme level. Fluvoxamine 15-26 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 106-112 10550852-5 1999 Of the SSRIs, fluvoxamine is one of the most potent inhibitors of the isoenzyme CYP 1A2. Fluvoxamine 14-25 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 80-87 9868741-1 1998 The selective serotonin re-uptake inhibitor, fluvoxamine, is a very potent inhibitor of CYP1A2, and accordingly causes pharmacokinetic interactions with drugs metabolised by CYP1A2, such as caffeine, theophylline, imipramine, tacrine and clozapine. Fluvoxamine 45-56 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 88-94 10471171-8 1999 Fluvoxamine is a potent inhibitor of CYP1A2, a moderate inhibitor of CYP3A and a mild inhibitor of CYP2D6. Fluvoxamine 0-11 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 37-43 10192755-1 1999 OBJECTIVE: Evidence exists to suggest that fluvoxamine is metabolized by CYP1A2. Fluvoxamine 43-54 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 73-79 10192755-2 1999 The present study was undertaken in order to further elucidate the role of CYPIA2 in fluvoxamine disposition. Fluvoxamine 85-96 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 75-81 9868741-7 1998 The formation of 1,7-dimethylxanthine was virtually abolished by 10 microM of fluvoxamine, indicating that the N3-demethylation of caffeine is almost exclusively catalysed by CYP1A2. Fluvoxamine 78-89 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 175-181 9923577-1 1998 OBJECTIVE: The potent CYP1A2 inhibitor fluvoxamine has recently been shown also to be an effective inhibitor of the CYP2C19-mediated metabolism of the antimalarial drug proguanil in vivo. Fluvoxamine 39-50 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 22-28 9868741-1 1998 The selective serotonin re-uptake inhibitor, fluvoxamine, is a very potent inhibitor of CYP1A2, and accordingly causes pharmacokinetic interactions with drugs metabolised by CYP1A2, such as caffeine, theophylline, imipramine, tacrine and clozapine. Fluvoxamine 45-56 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 174-180 9757149-0 1998 Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping. Fluvoxamine 10-21 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 51-57 9757149-1 1998 OBJECTIVE: To determine the effect of 150 mg/day fluvoxamine on the activities of CYP1A2, CYP2D6, CYP3A, N-acetyltransferase-2 (NAT2), and xanthine oxidase (XO) by phenotyping with caffeine, dextromethorphan, and midazolam. Fluvoxamine 49-60 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 82-88 9757149-8 1998 For CYP1A2, CYP2D6, and CYP3A phenotypes, significant differences existed between baseline and fluvoxamine therapy. Fluvoxamine 95-106 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 4-10 9757149-9 1998 For CYP1A2, the mean urinary metabolite ratio (+/-SD) was 7.53 +/- 7.44 at baseline and 4.30 +/- 2.82 with fluvoxamine ( P = .012). Fluvoxamine 107-118 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 4-10 9757149-12 1998 For CYP1A2, CYP2D6, and CYP3A, fluvoxamine therapy changed the phenotyping measures by a median of -44.4%, 123.5%, and -34.4%, respectively. Fluvoxamine 31-42 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 4-10 9757149-13 1998 CONCLUSIONS: We concluded that fluvoxamine may cause significant inhibition of CYP1A2, CYP2D6, and CYP3A activity. Fluvoxamine 31-42 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 79-85 9817620-3 1998 Thus fluvoxamine, but not citalopram, fluoxetine, paroxetine and sertraline is a potent inhbitor of CYP1A2. Fluvoxamine 5-16 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 100-106 9817620-4 1998 Accordingly fluvoxamine has interactions with other drugs eliminated by CYP1A2 including caffeine, clozapine, olanzapine, theophylline, propranolol and tacrine. Fluvoxamine 12-23 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 72-78 9617978-0 1998 Determinants of interindividual variability and extent of CYP2D6 and CYP1A2 inhibition by paroxetine and fluvoxamine in vivo. Fluvoxamine 105-116 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 69-75 9617978-3 1998 The antidepressants paroxetine and fluvoxamine are potent in vitro inhibitors of CYP2D6 and CYP1A2 isozymes, respectively. Fluvoxamine 35-46 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 92-98 9617978-6 1998 The aim of this study was to assess the determinants of interindividual variability and extent of CYP2D6 and CYP1A2 inhibition during paroxetine and fluvoxamine treatment. Fluvoxamine 149-160 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 109-115 9617978-16 1998 The extent of inhibition of CYP2D6 and CYP1A2 by paroxetine and fluvoxamine, respectively, displayed a positive correlation with baseline enzyme activity (p < 0.05). Fluvoxamine 64-75 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 39-45 9617978-18 1998 These data indicate that paroxetine and fluvoxamine treatment with minimum clinically effective doses significantly inhibit CYP2D6 and CYP1A2, respectively. Fluvoxamine 40-51 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 135-141 9617978-19 1998 The extent of inhibition of CYP2D6 by paroxetine and of CYP1A2 by fluvoxamine is dependent in part on the baseline enzyme activity. Fluvoxamine 66-77 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 56-62 9617978-21 1998 Most patients treated with fluvoxamine (50-100 mg/day) will reach population minimums for CYP1A2 activity. Fluvoxamine 27-38 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 90-96 10022747-0 1998 Use of heterologously expressed human cytochrome P450 1A2 to predict tacrine-fluvoxamine drug interaction in man. Fluvoxamine 77-88 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 38-57 10022747-6 1998 The Ki of fluvoxamine on 1-hydroxytacrine formation rate observed with rH-CYP1A2 was similar to that observed with human liver microsome (0.35+/-0.05 versus 0.20+/-0.20 microM, respectively). Fluvoxamine 10-21 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 74-80 10022747-7 1998 Using the Km, Vmax and Ki determined with rH-CYP1A2, we calculated that fluvoxamine produced an inhibition of 1-, 2- and 4-hydroxytacrine formation rate of 91, 87 and 88%, respectively, in the range of tacrine and fluvoxamine concentrations observed in man. Fluvoxamine 72-83 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 45-51 10950475-3 1997 This suggests that cytochrome P450IID6 (CYP2D6), an enzyme that is strongly inhibited by FLX, preferentially metabolizes (R)-MTD, whereas CYP1A2, which is strongly inhibited by FLV, metabolizes both enantiomers. Fluvoxamine 177-180 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 138-144 9209244-2 1997 Fluvoxamine, a potent CYP1A2 inhibitor, may be coadministered with tacrine. Fluvoxamine 0-11 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 22-28 9435993-14 1997 Fluvoxamine, as a potent inhibitor of CYP1A2, can inhibit the metabolism of clozapine, resulting in higher plasma concentrations. Fluvoxamine 0-11 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 38-44 9442550-5 1997 With regard to interactions of SSRIs and clozapine, fluvoxamine, a potent inhibitor of cytochrome P450 1A2, gives rise to higher clozapine levels at an earlier time, compared to other SSRIs (paroxetine, fluoxetine and sertraline), which are potent cytochrome P450 2D6 inhibitors. Fluvoxamine 52-63 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 87-106 8968657-19 1996 Fluvoxamine inhibits with decreasing potency, CYP1A2, CYP2C19, CYP2D6 and CYP1A1, but it is also an inhibitor of CYP3A. Fluvoxamine 0-11 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 46-52 9105404-0 1997 Distinction of CYP1A1 and CYP1A2 activity by selective inhibition using fluvoxamine and isosafrole. Fluvoxamine 72-83 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 26-32 9105404-5 1997 Isosafrole and fluvoxamine were found to inhibit CYP1A2 selectively, with Ki values of 14 and 800 times, respectively, lower than those for CY1A1. Fluvoxamine 15-26 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 49-55 9029748-7 1997 Fluvoxamine is a potent inhibitor of CYP1A2, and period B was included as a positive control. Fluvoxamine 0-11 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 37-43 9032002-8 1996 Fluvoxamine is a substantial inhibitor of CYP1A2 and CYP2C19, and a moderate inhibitor of CYP3A3/4. Fluvoxamine 0-11 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 42-48 8823236-0 1996 Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity. Fluvoxamine 15-26 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 93-99 8823236-2 1996 This study investigated the relationship between fluvoxamine disposition and the polymorphic CYP2D6 and the polycyclic aromatic hydrocarbon (as contained in cigarette smoke) inducible CYP1A2. Fluvoxamine 49-60 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 184-190 8823236-7 1996 The oral clearance of fluvoxamine correlated to the CYP1A2 index in the 14 subjects (rs = 0.58; p < 0.05; Spearman rank correlation). Fluvoxamine 22-33 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 52-58 8823236-8 1996 CONCLUSION: The disposition of fluvoxamine in humans is associated with the polymorphic CYP2D6 activity, but CYP1A2 also seems to be involved. Fluvoxamine 31-42 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 109-115 8610817-5 1996 Cytochrome P450 1A2 is inhibited by fluvoxamine and is implicated in drug interactions with theophylline, clozapine, and others. Fluvoxamine 36-47 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 0-19 8732441-3 1996 Thus, among the SSRIs, fluvoxamine is the only very potent inhibitor of cytochrome P4501A2 (CYP1A2). Fluvoxamine 23-34 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 72-90 8732441-3 1996 Thus, among the SSRIs, fluvoxamine is the only very potent inhibitor of cytochrome P4501A2 (CYP1A2). Fluvoxamine 23-34 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 92-98 8880055-0 1996 Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Fluvoxamine 83-94 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 29-35 8880055-13 1996 CONCLUSION: This investigation confirms that paroxetine and fluoxetine are potent inhibitors of CYP2D6, that fluvoxamine and fluoxetine are moderate inhibitors of CYP2C19 and that fluvoxamine is a potent inhibitor of CYP1A2 in humans in vivo. Fluvoxamine 180-191 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 217-223 8880055-1 1996 OBJECTIVE: The purpose of this pharmacokinetic study was to investigate the dose-dependent inhibition of model substrates for CYP2D6, CYP2C19 and CYP1A2 by four marketed selective serotonin reuptake inhibitors (SSRIs): citalopram, fluoxetine, fluvoxamine and paroxetine. Fluvoxamine 243-254 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 146-152 7586931-1 1995 OBJECTIVES: Although fluvoxamine inhibits the biotransformation of drugs known to be metabolized by CYP1A2, there are no data available with regard to the importance of CYP1A2 for the metabolism of fluvoxamine itself. Fluvoxamine 21-32 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 100-106 7586931-2 1995 Because smoking induces the metabolism of drugs catalyzed by CYP1A2, this study investigated the pharmacokinetics of fluvoxamine in smokers and nonsmokers. Fluvoxamine 117-128 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 61-67 7586931-8 1995 This finding is consistent with a possible role of CYP1A2 in fluvoxamine metabolism. Fluvoxamine 61-72 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 51-57 7622807-3 1995 Fluvoxamine interacts with these drugs by a mechanism involving inhibition of CYP1A2, CYP3A4, and CYP2C19. Fluvoxamine 0-11 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 78-84 7617560-0 1995 Kinetics and inhibition by fluvoxamine of phenacetin O-deethylation in V79 cells expressing human CYP1A2. Fluvoxamine 27-38 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 98-104 7742153-7 1995 Fluvoxamine was a potent inhibitor of CYP1A2-mediated 7-ethoxyresorufin O-deethylase activity (IC50 = 0.3 microM) in human liver. Fluvoxamine 0-11 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 38-44 7742153-13 1995 Ethanol and fluvoxamine both inhibited 8-hydroxylation by about 45% and, in combination, the compounds decreased the formation of 1,3-dimethyluric acid by 90%, indicating that CYP1A2 and CYP2E1 are equally important isoforms for the 8-hydroxylation of theophylline. Fluvoxamine 12-23 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 176-182 7742153-15 1995 It is concluded that pharmacokinetic interaction between fluvoxamine and theophylline is due to potent inhibition of CYP1A2. Fluvoxamine 57-68 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 117-123 8846617-17 1995 Fluvoxamine inhibits oxidative drug metabolising enzymes (particularly CYP1A2, and less potently and much less potently CYP3A4 and CYP2D6, respectively) and has the potential for clinically significant drug interactions. Fluvoxamine 0-11 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 71-77 8846618-11 1995 Consistent with its minimal in vitro effect on CYP2D6, fluvoxamine shows minimal in vivo pharmacokinetic interaction with desipramine, but does interact with imipramine (approximately 3- to 4-fold increase in AUC) through inhibition of CYP3A3/4, CYP1A2, and CYP2C19. Fluvoxamine 55-66 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 246-252 8846619-4 1995 Fluvoxamine is a potent inhibitor of CYP1A2, and there is potential for interaction with drugs that are metabolised by this isoenzyme. Fluvoxamine 0-11 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 37-43 8846619-5 1995 This property of fluvoxamine may be usefully applied to identifying agents that are substrates of CYP1A2, and it has a possible therapeutic application in the prevention of CYP1A2-mediated toxic metabolite formation. Fluvoxamine 17-28 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 98-104 8846619-5 1995 This property of fluvoxamine may be usefully applied to identifying agents that are substrates of CYP1A2, and it has a possible therapeutic application in the prevention of CYP1A2-mediated toxic metabolite formation. Fluvoxamine 17-28 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 173-179 8846620-11 1995 Those agents metabolised by cytochrome P450 1A2 isoenzyme appear most likely to be involved in drug-drug interactions with fluvoxamine. Fluvoxamine 123-134 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 28-47 8567194-5 1995 As shown in another simple table, the author compared the hepatic enzymatic inhibitions of four selective serotonin reuptake inhibitors and pointed out the inhibition potentials of fluvoxamine at CYP1A2, fluoxetine and paroxetine at CYP2D6, and fluoxetine and fluvoxamine at CYP3A4 if these two SSRIs have higher serum concentrations. Fluvoxamine 181-192 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 196-202 8466541-0 1993 Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Fluvoxamine 0-11 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 37-55 7974626-12 1994 The pathways are not known with certainty, but CYP1A2 may be of major importance for the metabolism of clozapine, since fluvoxamine is a potent inhibitor of this enzyme. Fluvoxamine 120-131 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 47-53 8466541-2 1993 The present study demonstrates that fluvoxamine is a very potent inhibitor of the high-affinity O-deethylation of phenacetin, which is catalysed by cytochrome P4501A2 (CYP1A2), in microsomes from three human livers. Fluvoxamine 36-47 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 148-166 8466541-2 1993 The present study demonstrates that fluvoxamine is a very potent inhibitor of the high-affinity O-deethylation of phenacetin, which is catalysed by cytochrome P4501A2 (CYP1A2), in microsomes from three human livers. Fluvoxamine 36-47 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 168-174 8466541-5 1993 Our findings explain the mechanism of the pharmacokinetic interactions between fluvoxamine and drugs that are metabolized by CYP1A2, e.g. theophylline and imipramine. Fluvoxamine 79-90 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 125-131 34564289-7 2021 Fluvoxamine is one of the most potent inhibitors of CYP1A2 and can lead to an increase in clozapine levels. Fluvoxamine 0-11 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 52-58 31172535-5 2019 Following a single oral dose of 3 mg, avadomide exposure when coadministered with the CYP1A2 inhibitor fluvoxamine was 154.81% and 107.59% of that when administered alone, for area under the plasma concentration-time curve from time 0 to infinity (AUC0-inf ) and maximum observed plasma concentration (Cmax ), respectively. Fluvoxamine 103-114 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 86-92 33302490-0 2020 A Physiologically-Based Pharmacokinetic (PBPK) Model Network for the Prediction of CYP1A2 and CYP2C19 Drug-Drug-Gene Interactions with Fluvoxamine, Omeprazole, S-mephenytoin, Moclobemide, Tizanidine, Mexiletine, Ethinylestradiol, and Caffeine. Fluvoxamine 135-146 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 83-89 35362343-0 2022 Fluvoxamine used to treat COVID-19 resulting in theophylline toxicity from CYP 1A2 drug-drug interaction. Fluvoxamine 0-11 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 75-82 30762305-0 2019 Physiologically-Based Pharmacokinetic Models for CYP1A2 Drug-Drug Interaction Prediction: A Modeling Network of Fluvoxamine, Theophylline, Caffeine, Rifampicin, and Midazolam. Fluvoxamine 112-123 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 49-55 31182321-2 2019 Smoking induces CYP1A2 thereby increasing clozapine metabolism whereas fluvoxamine inhibits CYP1A2. Fluvoxamine 71-82 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 92-98 26099559-1 2015 Co-administration of fluvoxamine (FLV) (perpetrator) and ramelteon (victim, high-clearance CYP1A2 substrate) reportedly showed a 130-fold increase in the area under blood-ramelteon-levels curve (AUCR), which is unpredictable by any method assuming the traditional well-stirred hepatic extraction (Eh ) model. Fluvoxamine 21-32 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 91-97 29155491-8 2018 Similarly, fluvoxamine (10 muM) readily inhibited CLZ oxidation in seven livers with high CYP1A2-mediated 7-ethoxyresorufin O-deethylation activity (at or above the median) and three livers with lower intrinsic CYP1A2 activity. Fluvoxamine 11-22 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 90-96 29155491-8 2018 Similarly, fluvoxamine (10 muM) readily inhibited CLZ oxidation in seven livers with high CYP1A2-mediated 7-ethoxyresorufin O-deethylation activity (at or above the median) and three livers with lower intrinsic CYP1A2 activity. Fluvoxamine 11-22 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 211-217 29101463-2 2018 This study was performed to investigate the potential drug-drug interaction of dovitinib with the CYP1A2 inhibitor fluvoxamine in patients with advanced solid tumors. Fluvoxamine 115-126 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 98-104 27821711-6 2017 Using this information, a clinical study using the CYP1A2 inhibitor fluvoxamine was performed, resulting in an AUCi/AUC ratio of 1.60, confirming the role of CYP1A2 and indicating a balanced DDI risk profile. Fluvoxamine 68-79 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 51-57 27821711-6 2017 Using this information, a clinical study using the CYP1A2 inhibitor fluvoxamine was performed, resulting in an AUCi/AUC ratio of 1.60, confirming the role of CYP1A2 and indicating a balanced DDI risk profile. Fluvoxamine 68-79 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 158-164 26886336-1 2016 Fluvoxamine-perpetrated drug-drug interactions (DDIs) of victims metabolized by multiple cytochrome P450 isoforms (CYP1A2, CYP2C19, and CYP3A4) were simulated using 2 compartment-based tube modeling, assuming a multiple inhibition-constant (Ki) model, as well as a previously reported single Ki model. Fluvoxamine 0-11 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 115-121 26626327-2 2016 Fluvoxamine is a potent CYP1A2 inhibitor and may increase the ratio of clozapine to its primary metabolite N-desmethylclozapine (NDMC). Fluvoxamine 0-11 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 24-30 26099559-1 2015 Co-administration of fluvoxamine (FLV) (perpetrator) and ramelteon (victim, high-clearance CYP1A2 substrate) reportedly showed a 130-fold increase in the area under blood-ramelteon-levels curve (AUCR), which is unpredictable by any method assuming the traditional well-stirred hepatic extraction (Eh ) model. Fluvoxamine 34-37 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 91-97 25719307-5 2015 Fluoxetine and norfluoxetine are also potent inhibitors of CYP2D6, and fluvoxamine is a potent inhibitor of both CYP1A2 and CYP2C19. Fluvoxamine 71-82 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 113-119 25159194-6 2015 Co-administration of pomalidomide with fluvoxamine (CYP1A2 inhibitor) in the presence of ketoconazole approximately doubled pomalidomide exposure. Fluvoxamine 39-50 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 52-58 24846087-3 2014 Here we present the case of a 29-year-old female patient with disorganized schizophrenia who exhibited OCS due to fluvoxamine-induced elevation of CLZ serum levels via inhibition of CYP 1A2 und 2C19. Fluvoxamine 114-125 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 182-189 24793403-7 2014 Two notable drug-drug interactions are evident: asenapine (an inhibitor of CYP2D6) can increase plasma levels of paroxetine, and fluvoxamine (a CYP1A2 inhibitor) can increase plasma levels of asenapine. Fluvoxamine 129-140 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 144-150 21979923-2 2011 Enzymes involved in duloxetine metabolism are cytochrome P450 isoenzymes (CYP) CYP1A2 and to a lesser extent CYP2D6 whereas the selective serotonin reuptake inhibitor Fluvoxamine is known to be a potent inhibitor of CYP1A2. Fluvoxamine 167-178 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 216-222 23001793-5 2013 Ketoconazole (inhibitor of CYP3A4/5) inhibited metabolism of (-)-THP or (+)-THP at same degree, whereas the inhibition of fluvoxamine (inhibitor of CYP1A2) on metabolism of (+)-THP was greater than that of (-)-THP; moreover, the metabolic rate of (+)-THP was 5.3-fold of (-)-THP in recombinant human CYP1A2. Fluvoxamine 122-133 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 148-154 23001793-5 2013 Ketoconazole (inhibitor of CYP3A4/5) inhibited metabolism of (-)-THP or (+)-THP at same degree, whereas the inhibition of fluvoxamine (inhibitor of CYP1A2) on metabolism of (+)-THP was greater than that of (-)-THP; moreover, the metabolic rate of (+)-THP was 5.3-fold of (-)-THP in recombinant human CYP1A2. Fluvoxamine 122-133 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 300-306 21979923-7 2011 Our findings indicate that duloxetine plasma levels can be enhanced by a potent CYP1A2 inhibition by FLX and that DLX, even in higher plasma levels, seems to be well tolerated. Fluvoxamine 101-104 cytochrome P450 family 1 subfamily A member 2 Homo sapiens 80-86